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For a long time, investigations about the lung myeloid compartment have been mainly limited to the macrophages located within
the airways, that is, the well-known alveolar macrophages specialized in recycling of surfactant molecules and removal of debris.
However, a growing number of reports have highlighted the complexity of the lung myeloid compartment, which also
encompass diﬀerent subsets of dendritic cells, tissue monocytes, and nonalveolar macrophages, called interstitial macrophages
(IM). Recent evidence supports that, in mice, IM perform important immune functions, including the maintenance of lung
homeostasis and prevention of immune-mediated allergic airway inﬂammation. In this article, we describe lung IM from a
historical perspective and we review current knowledge on their characteristics, ontogeny, and functions, mostly in rodents.
Finally, we emphasize some important future challenges for the ﬁeld.
1. From Septal Cells to Interstitial Macrophages
Phagocytic “septal cells” were observed by Kaplan and
colleagues already in 1950 [1] and likely represented “nonal-
veolar” macrophages located in the alveolar wall. Neverthe-
less, the alveolar macrophages (AM) remained the main
macrophage population investigated in the lung until the
early 1970s. By that time, it was proposed by van Furth and
Cohn that, like any other tissue-resident macrophages, AM
originated from bone marrow promonocyte precursors,
which then circulated in the blood as monocytes and could
diﬀerentiate into macrophages within the alveoli [2]. As a
corollary, an intermediate state of AM maturation, located
in the pulmonary interstitium, presumably existed between
the blood compartment and the airways. In 1972, “mononu-
clear interstitial cells” were ﬁrst proposed as precursors of the
AM lineage in cultured lung explants [3]. Since then, lung tis-
sue macrophages were long merely considered as a transition
state between circulating monocytes and AM [4–6].
The development of methods to harvest pulmonary
macrophages using mechanical and enzymatic treatments
allowed the comparison between AM (isolated by bronchoal-
veolar lavage (BAL)) and lung tissue macrophages (TM) in
rodents, even though the latter were contaminated by resid-
ual AM [7, 8]. While both AM and TM displayed classical
macrophage features such as a phagocytic potential and
expression of Fc receptors, these features were reduced in
TM as compared to AM [9–13]. Moreover, additional
diﬀerences were underscored within TM. In mice, TM exhib-
ited a higher percentage of cells positive for the complement
receptor C3 [8, 9], a higher production of arachidonic acid
metabolites following phagocytosis [14], and an increased
spreading capacity when exposed to plasma [9] as compared
to AM. In rats, TM were shown to have a higher peroxidase
activity [15], a greater major histocompatibility complex class
II (MHC-II) expression [16], and a greater number of ﬁlopo-
dia [17]. Upon ex vivo stimulation with lipopolysaccharide
(LPS), AM displayed greater cytotoxic and antimicrobial
activities than TM, while TM secreted more interleukin-
(IL-) 1 and IL-6, inmice [13] and rats [16]. Unlike AM,mouse
TM were also very potent in promoting mitogen-stimulated
spleen lymphocyte proliferation in mice [13]. Despite these
morphological, phenotypical, and functional diﬀerences,
many authors still interpreted them as being part of the tran-
sition process between blood-circulating monocytes and AM
[3–6, 13], but others raised the possibility that lung TM (also
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called interstitial macrophages (IM)) represented a distinct
and fully competent macrophage population [11, 16, 18], a
concept that is now well accepted in the ﬁeld [19–21].
2. Morphological and Phenotypical Features
Most of the abovementioned studies have been performed
ex vivo and have deﬁned TM as the cells collected from enzy-
matically digested lungs and adherent to the culture plate
in vitro. Obviously, such a technique did not allow a speciﬁc
isolation of IM, and the resulting cells were likely contami-
nated with variable amounts of other mononuclear cell types,
such as residual AM (despite extensive BAL [11, 22–24]),
conventional dendritic cells (cDCs), or monocytes [25, 26].
In addition, accepting that macrophages, once extracted
from their native microenvironment and cultured ex vivo,
undergo rapid morphological and phenotypical changes
[27], the conclusions drawn from ex vivo-cultured IM have
to be interpreted with caution.
Morphologically, Sebring and Lehnert were the ﬁrst, to
our knowledge, to combine a Fc receptor-based aﬃnity
technique with a cytometric approach to sort IM from
rat lungs and identiﬁed them as being smaller than AM,
with a smoother surface and a more irregular and
heterochromatin-containing nucleus [28]. More recently,
freshly isolated mouse IM were shown to exhibit an irregu-
larly shaped nucleus and numerous vacuoles in their cyto-
plasm, while mouse AM were larger cells [26] with more
prominent pseudopodia [29].
The availability of technologies allowing analysis of
freshly isolated single cells, such as multicolor ﬂow or mass
cytometry, substantially improved the phenotypic characteri-
zation of lung immune cells [20, 25, 26, 29–31]. The work of
several investigators in the ﬁeld has allowed, based on the
levels of expression of several surface markers, a discrimina-
tion between each of the lung myeloid mononuclear cell pop-
ulations in the steady-state lung, including IM (Figure 1).
These markers are compiled in Table 1. Both IM and AM
express the macrophage-speciﬁc markers CD64 and Mertk,
as opposed to cDCs andmonocytes.While AM are autoﬂuor-
escent SiglecF+CD11c+CD11b−CCR2−CX3CR1− cells, IM
are non-autoﬂuorescent SiglecF−CD11c+/−CD11b+CCR2+/−
CX3CR1+ cells [26, 31] (Figure 1). Notably, a recent report
has shown that a fraction of mouse IM, deﬁned as
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Figure 1: Mouse lung interstitial macrophage phenotype and origin at the steady state and upon exposure to LPS, CpG-DNA, or HDM.
For clarity, the ratio between the numbers of depicted AM, IM, and monocytes does not reﬂect the reality. By deﬁnition, IM are located
in the lung interstitium, while AM reside in the airway lumen. IM can produce IL-10 at baseline, a phenomenon that is potentiated by
an exposure to LPS, CpG-DNA [26], or HDM [50]. Phenotypically, IM are non-autoﬂuorescent SiglecF−CD11b+CX3CR1+Ly6C− cells,
while AM are autoﬂuorescent SiglecF+CD11c+CD11b−CX3CR1−Ly6C− cells. Steady-state IM, as well as LPS- or HDM-induced IM,
are thought to be maintained or expanded by the recruitment of CCR2-dependent Ly6C+ classical blood monocytes, at least in part.
Local proliferation may also account for the maintenance of steady-state IM. Following exposure to CpG-DNA, CCR2-independent
lung-resident and splenic Ly6C+ monocytes contribute to a large extent to the expansion of the IM pool endowed with enhanced
immunoregulatory properties.
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Mertk+CD64+CD11b+SiglecF− cells, expressed CD11c and
MHC-II [31], like cDCs, so that both cell types may poten-
tially contaminate each other. Nevertheless, cDCs diﬀer from
IM by their low or absent expression of macrophage markers
(e.g., CD64, Mertk, and F4/80). The situation may be more
confusing when inﬂammation is present and monocyte-
derived cells are inﬁltrating the lung, in which case IM may
be included in inﬂammatory subtypes of monocytes or DCs.
Nevertheless, IM may be discriminated from such cells by
their low expression of the inﬂammatory/classical monocyte
marker Ly6C.
3. Tissue Localization
At steady state, lung IM are primarily considered as “nonal-
veolar” macrophages and are therefore virtually absent in
the airways, while AM represent the macrophages present
in the airway lumen. To date, however, it must be noted that
information about the exact localization of IM within the
lung tissue remains scarce and is based on standard immuno-
histochemical procedures using nonspeciﬁc pan-macrophage
markers [31, 32]. Earlier studies in mice using immu-
nostainings against F4/80 and CD11c markers identiﬁed
F4/80+CD11c− cells, deﬁned as IM, within the lung paren-
chyma, whereas AM, deﬁned as F4/80+CD11c+ cells, were
mostly located in the lumen [32]. Experiments using intrave-
nous injection of clodronate-containing liposomes, which
eﬃciently depleted blood monocytes, had no impact on IM
numbers [26], supporting that steady-state IM were not asso-
ciated with blood vessels but truly located in the lung tissue.
More recently, Gibbings and colleagues have performed a
staining for Mertk on mouse lung sections from CX3CR1-
GFP reporter mice at steady state, allowing the visualization
of Mertk+CX3CR1+ IM in the bronchial interstitium, in the
vicinity of lymphatic vessels, but not in the lung parenchyma
[31]. In the same report, no Mertk+CX3CR1+ cells were
observed on the pleural surface nor in the blood vessels
[31]. Given the complexity and dynamic regulation of the
lung tissue macrophage compartment, the generation of
novel transgenic tools allowing the speciﬁc tracking and visu-
alization of IM in vivo will help solve the question of their
localization and their spatiotemporal relationships with the
local microenvironment, such as bronchial and alveolar
epithelial cells, stromal cells, endothelial cells, or lymphoid
tissues [33], at steady state and during inﬂammation. The fact
that distinct subpopulations of IM exist, as reported recently
[31], is consistent with the idea that they may reside in more
than one anatomical site.
4. Origin, Maintenance, and Expansion
Most tissue-resident macrophages are thought to derive from
embryonic precursors arising from diﬀerent sources: the yolk
sac (i.e., erythromyeloid progenitor- (EMP-) derived prema-
crophages), the fetal liver (i.e., EMP-derived monocytes or
hematopoietic stem cell- (HSC-) derived monocytes), or the
bone marrow (i.e., HSC-derived monocytes), as reviewed
and discussed extensively elsewhere [34–36]. At steady state,
the well-characterized AM have been shown, in mice, to
originate from fetal monocytes that seed the airway lumen
around birth [20]. On the contrary, IM ontogeny seems
more complicated and less documented. In 2016, Tan and
Krasnow investigated the development of lung macrophages
by marker expression patterns and genetic lineage tracing
[21]. The authors used Runx1CreER transgenic mice express-
ing the tamoxifen-inducible Cre recombinase under the con-
trol of the Runx1 promoter (Runx1 being expressed in
primitive hematopoietic cells located exclusively in the yolk
sac between E7 and E8 [37, 38]) and found that a subset of
yolk-sac-derived premacrophages seeded the lung starting
at E10.5 and persisted as “primitive” IM at speciﬁc subme-
sothelial and perivascular locations in adults [21]. In addition,
they identiﬁed an additional wave that developed rapidly after
birth to give rise to “deﬁnitive” IM located diﬀusely in the
lung parenchyma and thought to originate from the bone
marrow [21]. These results are consistent with the idea that
IM have a mixed origin, both an embryonic yolk-sac-
derived origin and a postnatal bone marrow-derived origin.
During homeostasis, most embryonically derived tissue-
residentmacrophages, like AM, can self-maintain throughout
life with minimal contribution from circulating monocytes
[20, 35, 39–41]. In the case of IM, parabiosis studies have
suggested that they are, at least in part, replenished from
blood monocytes for their maintenance in adults [21, 26]
(Figure 1), like macrophages from the intestinal lamina pro-
pria [42], skin [43], and heart [44]. In the report of Tan and
Krasnow, parabiotic wild-type (WT) mice were sutured
together and exchanged their circulation with “donor” ubiq-
uitous EGFP mice for 4 months. The lungs of WT mice were
then examined for enrichment in EGFP+ cells, and 17% of
IM were EGFP+, demonstrating that circulating precursors
can maintain the IM pool in adults, as opposed to AM
[21]. Further supporting this, our group has analyzed the
lungs of parabiotic Ccr2−/− mice (in which the egress of
monocytes from the bone marrow is compromised [45])
that were sutured together with a WT “donor” for 6 months
and showed that 35% of IM derived from WT cells. The
relatively low percentage of IM replacement by circulating
“donor” cells in parabiotic studies is consistent with the
mixed origin proposed by Tan and Krasnow [21] and with
the idea that only one subpopulation of IM is maintained
by circulating monocytes after birth, whereas another sub-
population is long-lived and may be able to self-renew in
the tissue (Figure 1). This idea is further supported by the
study of Gibbings and colleagues identifying, in the mouse
steady-state lung, at least three IM subsets, with one subset
displaying a higher turnover rate and replenishment by
circulating precursors than the two others [31].
Which population is preponderant in young, adult, and
aged animals, which consequences does it have on their bio-
logical functions, and how is it inﬂuenced by the numerous
immune challenges to which the lung is exposed throughout
life remain interesting open questions for future research.
Emphasizing the complexity of IM ontogeny in response
to environmental stimuli, our group reported that local
exposure to unmethylated CpG-rich DNA (CpG-DNA)
promoted a robust TLR-9-dependent expansion of IM
unexpectedly originating from monocytes residing in the
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lung or recruited from the spleen, independently of CCR2
[26] (Figure 1).
5. Heterogeneity and Plasticity
The existence of subpopulations of IM in rats was ﬁrst pro-
posed in 1986 by Chandler and colleagues [15] and further
investigated by the same group [46, 47], based on density gra-
dient fractionation. The fractions of lower density displayed
greater functional capacities (e.g., Fc-mediated binding and
phagocytic activity, production of prostaglandin and throm-
boxane, andmigration upon exposure to chemotactic stimuli)
as compared to the fractions of higher density [15, 46, 47].
However, it is unclear whether these diﬀerencesmay be attrib-
uted to a true heterogeneity within IM or to a contamination
of the higher density fractions with granulocytes, as reported
[15]. Nevertheless, several recent reports have provided
experimental evidence that IM represented a heterogeneous
population in the steady-state lung. First, the use of IL-10
reporter ITIB mice [48] supported that two subpopulations
of IM exist in terms of IL-10 expression [26]. Second, IM have
been shown to segregate in a phagocytic and a nonphagocytic
compartment in vivo [49]. Third, as stated above, Gibbings
and colleagues have recently described three distinct IM sub-
populations, based on their relative surface expression of
CD11c and MHC-II, namely, CD11clowMHC-IIlow (IM1),
CD11clowMHC-IIhigh (IM2), and CD11c+MHC-IIhigh (IM3)
[31]. Phenotypically, IM1 and IM2 expressed higher levels
of CD206, Lyve-1, and CD169 as compared to IM3, which
expressed higher levels of CCR2 and CD11c. Functionally,
IM1 and IM2 appeared to be more eﬃcient than IM3 but less
eﬃcient than AM in the phagocytosis of latex microbeads or
microbial bioparticles in vivo, whereas the three populations
had similar phagocytic abilities when the experiment was per-
formed ex vivo to provide a similar access to the beads for
each subset [31].
These results highlight the potential diversity of mouse
IM at steady state. It is very likely that the picture becomes
even more complex when the lungs are exposed to endoge-
nous or exogenous stress signals, such as following tissue
damage or during inﬂammation or infection. Under these
circumstances, IM may adapt their phenotype and function
to respond to the needs of the lung tissue, and additional
inﬂammatory monocytes may also be recruited into the lung
and acquire features of IM. Supporting this, Kawano and col-
leagues have shown that the numbers of IL-10-producing IM
were increased following local challenge with house dust mite
extracts (HDM) inmice [50]. In addition, we have shown that
local exposure of mice to LPS or CpG (i.e., ligands of the TLR-
4 and TLR-9, resp.) induced increases in IM numbers as well
as substantial phenotypical changes, while no change in IM
numbers was detected in response to lung infectionwith inﬂu-
enza A virus or Staphylococcus pneumoniae, or following
intranasal exposure to ligands of TLR-1/2, TLR-3, and TLR-
2/6 [26]. Besidesmicrobial products, IMmay also be impacted
by tissue damage and hypoxia [29, 51, 52]. Indeed, increases in
IM numbers have also been observed in mouse models of
acute lung injury (ALI) based on local instillations of bleomy-
cin [29] or high doses of LPS [51]. Such IM expressed higher
levels of classically activated “M1” macrophage markers
(CD40, CD80, and CD86) as compared to basal IM. During
the later stages of tissue repair, however, IM numbers and
phenotype returned to baseline levels [51]. In response to
low oxygen levels in mice, numbers of IM transiently
increased and their transcriptome seemed to shift toward an
anti-inﬂammatory gene proﬁle at a later stage [52], consistent
with a previous observation that the hypoxia-responsive tran-
scription factorHif1α promoted IM immunoregulatory activ-
ity in allergenic contexts [53].
6. Biological Functions In Vivo
Many putative functions of IM in vivo could be speculated
based on their phenotypical and functional properties. Like
AM, IM are phagocytic cells [14–16, 31, 32, 49, 54] and could
thus be considered as a second line of defense against invad-
ing microorganisms. In addition, based on their expression of
MHC-II [26, 31, 54], one can postulate that mouse IM could
exhibit some antigen-presenting cell activity, as suggested by
earlier reports [55]. So far, however, most of the functional
studies on IM in mice focused on their potential immunoreg-
ulatory properties. Indeed, mouse and human IM have been
shown to express the immunosuppressive cytokine IL-10 at
steady state [24–26, 32, 56] (Figure 1). Such IL-10 expression
increases in response to environmental stimuli such as LPS,
CpG-DNA, or HDM [26, 50, 56] (Figure 1). Knowing that
the lung mucosa is constantly exposed to a wide range of
immunostimulatory molecules and allergens, we postulated
that IM may contribute to lung homeostasis through the
alteration of lung cDC functions, which are endowed with
the ability to trigger an allergen-speciﬁc T helper type 2
(Th2) cell response orchestrating the development of aller-
gic airway inﬂammation in mice exposed to LPS and aller-
gens [57–60].
Using a coculture system between freshly isolated IM
and LPS- and ovalbumin- (OVA-) pulsed bone marrow-
derived DCs (BMDCs) in vitro, IM were found to impair
the ability of BMDCs to migrate to the draining lymph
node and to induce features of Th2-mediated airway allergy
once reinjected in the trachea of recipient mice through
TLR-4-, HIF1α-, and IL-10-dependent mechanisms [32].
Notably, while isolated and cocultured IM may have
encompassed other cell types such as F4/80-expressing
monocytes or resident eosinophils [26, 61], the “true” IM
were the only cells able to secrete IL-10, and the ability of
FACS-sorted pure IM to inhibit DC function has been con-
ﬁrmed later [26, 61]. In vivo, systemic treatment of WT
mice with depleting antibodies directed against F4/80
induced a depletion of IM, but not AM, and triggered
increased activation of lung cDCs and the development of
overt Th2 and allergic airway inﬂammation when mice
were exposed to low doses of an allergen/LPS mixture
[32], further supporting a tolerogenic role for IM in main-
taining lung homeostasis.
Mouse IM may be implicated in the control not only of
allergic asthma in mice but also of other asthma phenotypes.
Indeed, Kawano and colleagues have provided evidence
that IM contributed to the prevention of Th17-mediated
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neutrophilic airway inﬂammation by IL-10-dependent
mechanisms [50]. They used a neutrophilic asthma model
based on HDM instillations in Il10−/− mice, which dramat-
ically increased the number of neutrophils in the BAL
ﬂuid and promoted lung neutrophilic inﬁltration and
expression of Th17-related cytokines as compared to
HDM-exposed WT mice. In this model, they showed that
the transfer of WT IM in Il10−/− mice before the HDM
challenge could inhibit the neutrophilic inﬂammation and
mucus production, which was associated with a decrease
of Th17-related cytokines and IL-13 [50].
The fact that IM respond to LPS and CpG-DNA, two
bacterial products omnipresent in the environment [62, 63],
suggests a link with the “hygiene hypothesis,” which postu-
lates that decreased exposure to environmental and com-
mensal microbes or their products (PAMPs), partly because
of changes associated with urban lifestyles, is responsible
for the dramatic increase in the prevalence of allergies and
asthma over the past decades [64, 65]. In line with this
assumption, several epidemiological studies have demon-
strated that growing up on a farm, where exposure to envi-
ronmental and commensal PAMPs is high, reduces the risk
of allergic sensitization [62, 65]. Exposure of humans or mice
to CpG-DNA from bacteria reproduces these protective
eﬀects [66–71], suggesting a contribution of CpG-DNA to
microbe-induced asthma resistance. In mouse models, local
CpG-DNA exposure had the unique ability to amplify the
IM pool from monocytes residing in the lung or recruited
from the spleen, which acquired a hypersuppressive proﬁle
[26]. Importantly, such CpG-DNA-induced IM were sug-
gested to mediate the protective eﬀects of CpG-DNA on
allergic airway sensitization and inﬂammation, since adop-
tive transfer of IM isolated from CpG-DNA-treated WT
mice, unlike the Il10−/− counterparts, recapitulated the eﬀects
of CpG when administered before allergen sensitization or
challenge [26]. While speculative at this point, these ﬁndings
provide a possible mechanistic explanation for the reduced
risk of asthma in a microbe-rich environment and for the
immunotherapeutic eﬀects of synthetic CpG-DNA in exper-
imental models and human clinical trials.
7. IM in Human and Nonhuman Primates
IM were already observed more than three decades
ago in lungs from healthy subjects [72] or diseased
patients [73, 74]. By that time, the functional studies com-
paring human lung macrophages obtained from the BAL
and from the whole lung revealed very few diﬀerences
between BAL-derived AM and tissue IM, possibly because
tissue macrophages were heavily contaminated by residual
AM [74].
Like in rodents, IM isolated from minced and digested
human lungs are smaller and more heterogeneous in shape
[54, 56], displayed a lower phagocytic activity [54], and
expressed more surface MHC-II (HLA-DR) [56, 75] as
compared to AM. Lung IM, which were obtained from the
uninvolved lung tissue of patients undergoing a surgical
resection for lung carcinoma and put in contact with stimu-
lated T cell membranes, produced higher levels of matrix
metalloproteinases (MMPs) and of an inhibitor of MMP
(TIMP-1), whereas AM did not signiﬁcantly react under
the same conditions [75], suggesting a possible contribution
of human IM in the regulation of lung tissue remodeling.
Hoppstädter and colleagues showed that the secreted
levels of IL-6, IL-10, and IL-1 receptor antagonist (IL-1Ra)
were higher in IM than in AM, both at baseline and after
stimulation with LPS [56]. Il10 gene expression was also
higher in IM at baseline and after stimulation with
LPS or DNA from certain bacteria [56], reminiscent of
what is observed in mice. On the contrary, AM secreted
higher levels of proinﬂammatory cytokines, such as IL-1β,
IFN-γ, IL-12p40, or IL-12p70, after LPS stimulation [56].
Altogether, these results supported a more pronounced
anti-inﬂammatory phenotype of IM as compared to AM
and are consistent with a potential role for IL-10-producing
IM in the maintenance of lung homeostasis in humans.
Interestingly, a recent study performed on bronchial biopsies
of asthmatic patients and healthy subjects showed that
asthmatic airways were characterized by less IL-10+ IM as
compared with healthy airways, suggesting that IM may be
functionally impaired in asthma [76].
Given the limited access to healthy human samples,
Cai and colleagues performed some studies on rhesus
macaques as a model to unravel the human lung macro-
phage identity and diversity [5]. IM were deﬁned as
HLA-DRhighCD206−/intCD11bhigh cells and were located in
the peribronchovascular and subpleural regions, whereas
AMs were deﬁned as CD206+CD11bint larger cells that were
located almost exclusively in the alveoli. Notably, the IM
population had probably been confounded with tissue mono-
cytes in this study, since IM and CD14+ blood monocytes
resembled each other when analyzing the expression of 27
diﬀerent markers, with the exception of CCR2 being highly
expressed by blood monocytes and poorly by IM. This could
also account for the fact that “IM” were found positive for
BrdU as soon as 48 hours after its intravenous injection
and were thought to contribute to the repopulation of AM
after BAL-induced depletion [5].
Recent reports are aimed at identifying markers to dis-
criminate IM from other lung monocyte and macrophage
populations in human pulmonary tissue. In humans, AM
and monocytes can be deﬁned as highly autoﬂuorescent
SSChiCD169hiCD206hi and SSCloCD169−CD206−CD14+-
CD16lo/hi cells, respectively [77–79]. In addition, a popula-
tion of HLA-DR+CD169loCD206int cells was identiﬁed in
the human lung, whose size was intermediate between AM
and monocytes [77–79] and which may correspond to
human IM [77, 79]. Functional studies of these cells could
help in determining their homology with murine IM. Human
lung macrophages of COPD patients were also characterized
recently [80]. In this report, “IM” were shown to be divided
into two subpopulations: a scarce population of large macro-
phages, which expressed more CD206, and a population of
small macrophages, potentially monocyte-derived, express-
ing more HLA-DR, CD14, CD38, CD36, and proinﬂamma-
tory genes as compared to the other lung macrophages
[80]. While this study has mainly focused on the analysis of
pathological tissues, it emphasizes the complexity of the IM
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pool in diseased patients. It also suggests that IM can exert
either anti- or proinﬂammatory properties, depending on
the physiological or pathological conditions to which they
are exposed.
8. Future Challenges
While substantial progress has been made regarding the
ontogeny, phenotype, and functions of IM in mice, it is only
the beginning of the story. First, to date, IM or IM subsets
have been only characterized as bulk populations, deﬁned
according to a limited number of markers, thus revealing
average signatures and ignoring the true and unbiased het-
erogeneity and structure of the populations of interest. There
is therefore a need for an unbiased characterization of the IM
population, both in mice and humans. Recent development
and availability of high-dimensional single-cell technologies
[81, 82] should help study highly diverse and heterogeneous
immune cells such as IM.
Second, the biological responses modulated by IM or IM
subpopulations in vivo remain rudimentarily investigated
but are likely highly diverse and complex. This is partly due
to the current lack of selective tools to track, modulate, or
deplete IM (or IM subsets) in animal models, which will be
instrumental in deciphering the biological functions of IM
in health and diseases. On the one hand, IM may contribute
to important physiological processes during lung develop-
ment, metabolism, or aging. On the other hand, IM may also
modulate several aspects of the pathological responses
observed in lung chronic inﬂammatory disorders such as
chronic obstructive pulmonary diseases (COPD).
Third, translational studies aimed at deﬁning lung IM
identity, heterogeneity, and functions in humans will be
essential to ﬁnd novel therapeutic targets for the prevention
or treatment of lung diseases in which IM (dys)functions
are, or will be, implicated.
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